Pregnancy in Classical Paroxysmal Nocturnal Hemoglobinuria and Aplastic Anemia-Paroxysmal Nocturnal Hemoglobinuria: A High-Risk Constellation.
aplastic anemia (AA)
eculizumab
paroxysmal nocturnal hemoglobinuria (PNH)
pregnancy
thrombosis
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2020
2020
Historique:
received:
16
03
2020
accepted:
20
08
2020
entrez:
26
10
2020
pubmed:
27
10
2020
medline:
27
10
2020
Statut:
epublish
Résumé
Pregnancies in paroxysmal nocturnal hemoglobinuria (PNH) are associated with increased morbidity and mortality. Retrospective studies suggest that outcome has improved with the advent of the complement inhibitor eculizumab. To substantiate this assumption we analyzed the data from patients treated in our department since 2009. All patients were included in the International PNH registry and followed prospectively. We identified 16 pregnancies in 9 patients with classical PNH, and two pregnancies in two patients with aplastic anemia (AA)-PNH. In classical PNH, 13 pregnancies were supported by eculizumab. Breakthrough hemolysis occurred in six pregnancies, necessitating an increase in the biweekly eculizumab dose from 900 mg to 1,200-1,800 mg. Red blood cell transfusions were given in six and platelet transfusions in two pregnancies. A Budd-Chiari syndrome and cholecystitis complicated the course of two pregnancies. Four of 13 pregnancies supported by eculizumab ended in spontaneous abortion or stillbirth, and one was prematurely terminated because of fetal trisomy 21. None of the three pregnancies not supported by eculizumab had a successful outcome. Half the deliveries were preterm. None of the patients died, and, in all but one patient, the post-partum period was uneventful. Both pregnancies in patients with AA-PNH took a favorable course. Our results confirm low maternal mortality and frequent breakthrough hemolysis in pregnant PNH patients receiving eculizumab. Fetal mortality and the rate of preterm delivery were higher than reported previously, possibly related to the use of registry data that are likely to reduce the risk of publication and recall biases.
Identifiants
pubmed: 33102497
doi: 10.3389/fmed.2020.543372
pmc: PMC7546795
doi:
Types de publication
Journal Article
Langues
eng
Pagination
543372Informations de copyright
Copyright © 2020 Alashkar, Saner, Vance, Schmücker, Herich-Terhürne, Dührsen, Köninger and Röth.
Références
Mol Immunol. 1996 Dec;33(17-18):1389-401
pubmed: 9171898
Br J Exp Pathol. 1975 Oct;56(5):389-95
pubmed: 1212421
N Engl J Med. 2015 Sep 10;373(11):1032-9
pubmed: 26352814
Int J Hematol. 2016 Jun;103(6):703-12
pubmed: 26857155
Br J Haematol. 2003 Dec;123(5):782-801
pubmed: 14632769
Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):208-216
pubmed: 27913482
N Engl J Med. 2018 Oct 25;379(17):1643-1656
pubmed: 30354958
Haemostasis. 2000 May-Jun;30(3):103-17
pubmed: 11014960
Nephrology (Carlton). 2020 Jun;25(6):435-441
pubmed: 32133725
Nat Rev Dis Primers. 2017 May 18;3:17028
pubmed: 28516949
Cardiovasc Diagn Ther. 2017 Dec;7(Suppl 3):S309-S319
pubmed: 29399535
Mol Immunol. 2010 Apr;47(7-8):1500-6
pubmed: 20181396
Blood. 2012 Aug 9;120(6):1185-96
pubmed: 22517900
Front Immunol. 2019 Jun 14;10:1157
pubmed: 31258525
Ann Intern Med. 2002 Aug 6;137(3):164-72
pubmed: 12160364
Haematologica. 2011 Sep;96(9):1276-83
pubmed: 21606169
Clin Appl Thromb Hemost. 2018 Sep;24(6):850-858
pubmed: 29758989
Obstet Gynecol Surv. 1976 Jul;31(7):523-8
pubmed: 781567
Obstet Gynecol Surv. 2006 Sep;61(9):593-601
pubmed: 16919177
N Engl J Med. 2004 Feb 5;350(6):552-9
pubmed: 14762182